Instead of waiting for a physical change in the body, breath biomarkers (based on metabolomics) become the earliest detection method.
This method reads the body at the chemical level, earlier than the appearance of physical symptoms.
We can measure the genetic cancer biomarkers that cells emit (even in a small number of dying cells or low DNA release) through the breath.
Earlier detection unlocks both affordable treatment pathways and better long-term patient prognosis.
25 of every 100 women tested are given a false positive or false negative diagnosis.
Mammography can identify an abnormality that looks like cancer but turns out to be normal.
This “false alarm” means more tests and follow-up visits, which increase stress levels.
BreathLabs is an electronic nose with 32 nano-sensors. These sensors are 200,000 times more sensitive than a human nose and can “smell” the volatile organic compounds in human breath in less than 15 minutes.
Our patented multivariate canonical analysis algorithm, hardware technology, artificial intelligence, and machine learning tools allow BreathLabs™ to produce a result with an initial 85% accuracy, significantly better than mammography.
Machine learning makes the algorithm more accurate with every test made.
Easy-to-use ensures new users learn to use prototyping tools.
